For the Quarter Ending March 2026
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q1 2026, driven by elevated production costs.
- The Lorazepam Production Cost Trend increased in March 2026 as the Producer Price Index rose 4.0%.
- The Lorazepam Demand Outlook strengthened in March 2026, supported by a 3.3% Consumer Price Index increase.
- Retail sales grew 4.0% and unemployment reached 4.3% in March 2026, sustaining Lorazepam prescription affordability.
- Industrial production grew 0.7% and the Manufacturing Index expanded in March 2026, supporting Lorazepam supply chains.
- Benzene feedstock and natural gas costs surged in January 2026, directly elevating the Lorazepam Price Index.
- The Lorazepam Price Forecast remained upward in Q1 2026 due to tightened injectable supply and manufacturing delays.
Why did the price of Lorazepam change in March 2026 in North America?
- Elevated patient demand for anxiety treatments drove Lorazepam prescription volumes significantly higher throughout Q1 2026.
- International supply chain issues and pharmaceutical ingredient sourcing delays slowed domestic production in Q1 2026.
- Natural gas prices and benzene feedstock costs rose sharply in January 2026, increasing manufacturing expenses.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index rose quarter over quarter in Q1 2026, reflecting upstream feedstock surges.
- The Lorazepam Production Cost Trend increased in March 2026 as upstream crude oil and naphtha prices surged.
- A 0.5% Producer Price Index rise in March 2026 elevated manufacturing expenses for Lorazepam chemical precursors.
- The Lorazepam Demand Outlook expanded in Q1 2026, supported by a 1.0% Consumer Price Index increase.
- The Manufacturing Index expanded in March 2026, while industrial production grew 5.7%, ensuring steady Lorazepam supply.
- Slower retail sales growth of 1.7% in March 2026 marginally reduced pharmacy foot traffic for treatments.
- The Lorazepam Price Forecast remained elevated in Q1 2026 as buyers sought alternative Middle Eastern cargoes.
Why did the price of Lorazepam change in March 2026 in APAC?
- Global crude oil markets experienced a massive energy supply shock in March 2026, disrupting stability.
- Naphtha feedstock costs experienced a substantial increase in Q1 2026, elevating benzene value chain expenses.
- Domestic benzene discussion levels surged in March 2026 as buyers scrambled to secure forward cargoes.
Lorazepam Prices in Europe
- In Germany, the Lorazepam Price Index rose quarter-over-quarter in Q1 2026, driven by surging chemical precursor costs.
- The Lorazepam Production Cost Trend increased in March 2026 as 2.7% inflation elevated pharmaceutical manufacturing operational costs.
- Despite producer prices declining 0.2% in March 2026, benzene and ammonia precursor costs surged across the region.
- The Manufacturing Index expanded in March 2026, ensuring stable supply chains for final packaged retail Lorazepam products.
- Industrial production remained stagnant at 0.0% in February 2026, while domestic pharmaceutical output plummeted in January 2026.
- Retail sales grew 0.7% in February 2026, supporting steady consumer spending and retail pharmacy oral Lorazepam purchases.
- The Lorazepam Price Forecast indicated upward pressure in Q1 2026 due to tightened regional ammonia chemical inventories.
Why did the price of Lorazepam change in March 2026 in Europe?
- European spot costs for benzene, a critical Lorazepam feedstock, surged significantly regionally in March 2026.
- Ammonia supply tightened across Europe in March 2026 following widespread regional outages and severe bottlenecks.
- Crude oil prices surged in March 2026, intensifying upstream cost pressures for European petrochemical feedstocks.
For the Quarter Ending December 2025
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q4 2025, driven by rising production costs.
- Lorazepam production costs increased due to a 3.0% year-over-year PPI rise in November 2025, impacting inputs.
- Consumer prices, indicated by a 2.7% year-over-year CPI increase in December 2025, raised general manufacturing expenses.
- Lorazepam demand was supported by a 3.3% year-over-year increase in retail sales in November 2025.
- A 4.4% unemployment rate in December 2025 indicated a strong labor market, enhancing Lorazepam affordability.
- Industrial production increased 2.0% year-over-year in December 2025, supporting pharmaceutical supply chains.
- Manufacturing output declined annually in Q4 2025, reflecting broader US chemical production headwinds.
- Colder weather influenced Henry Hub natural gas spot prices in December 2025; futures softened, reducing supply concerns.
Why did the price of Lorazepam change in December 2025 in North America?
- Rising production costs were driven by a 3.0% year-over-year PPI increase in November 2025, affecting Lorazepam inputs.
- Strong consumer spending, evidenced by a 3.3% year-over-year retail sales increase in November 2025, supported demand.
- Softening Henry Hub natural gas futures prices in December 2025 after an early peak influenced energy costs.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index fell quarter-over-quarter in Q4 2025, driven by declining producer prices.
- Lorazepam production costs declined in December 2025, as producer prices fell 1.9% year-over-year.
- The Lorazepam demand outlook remained subdued in Q4 2025, with retail sales growing 0.9% in December 2025.
- Weak inflationary pressure, with CPI at 0.8% in December 2025, contributed to stable overall healthcare costs.
- Consumer sentiment cooled in Q4 2025, impacting spending, alongside 5.1% unemployment in December 2025.
- Manufacturing activity expanded in December 2025, supported by a 5.2% rise in industrial production.
- Global petrochemical feedstock demand was less robust in 2025, easing Lorazepam production cost pressures.
- China's basic petrochemical supply strengthened in 2025, with increased exports impacting trade flows.
- Oil inventories experienced further builds in December 2025, indicating ample energy supply.
Why did the price of Lorazepam change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing manufacturing costs.
- Subdued overall consumer demand in China in Q4 2025 impacted Lorazepam's market demand.
- Less robust global petrochemical feedstock demand in 2025 contributed to lower input costs.
Lorazepam Prices in Europe
- In Germany, the Lorazepam Price Index fell quarter-over-quarter in Q4 2025, influenced by weak industrial demand in October 2025.
- Lorazepam production costs declined in December 2025, as the Producer Price Index (PPI) decreased by 2.5% year-over-year.
- Operational costs for Lorazepam manufacturers increased in December 2025 due to a 1.8% year-over-year rise in the Consumer Price Index (CPI).
- The Lorazepam demand outlook remained constrained in Q4 2025, with the Manufacturing Index contracting in December 2025.
- Industrial production grew 0.8% year-over-year in October 2025, supporting stable supply chains, while retail sales rose 1.1% in November 2025.
- Consumer confidence remained pessimistic at -17.5 in December 2025, affecting healthcare spending and Lorazepam access.
- Germany's unemployment rate of 6.2% in December 2025 indicated economic slack, potentially straining public healthcare budgets.
- The Lorazepam Price Index is forecast to remain under pressure, given persistent weak demand and high competitive intensity in Q4 2025.
Why did the price of Lorazepam change in December 2025 in Europe?
- Producer Price Index (PPI) decreased by 2.5% year-over-year in December 2025, reducing manufacturing input costs.
- Contracting Manufacturing Index in December 2025 and weak industrial economy weighed on overall chemical demand.
- Increased competitive pressure from abroad forced German chemical companies to lower prices in October 2025.
For the Quarter Ending September 2025
Lorazepam Prices in North America
- In United States, the Lorazepam Price Index rose quarter-over-quarter in Q3 2025, driven by increasing production costs and shrinking inventories.
- Rising CPI (3.0% in September 2025) indicated higher operational costs for Lorazepam manufacturers.
- Producer Price Index (2.6% in August 2025) increased raw material costs for Lorazepam production.
- US natural gas prices saw an uptick in Q3 2025, increasing Lorazepam production expenses.
- Chemical manufacturers reported shrinking inventories in Q3 2025 due to accelerating destocking, impacting Lorazepam supply.
- US pharmaceutical exports increased in August 2025, while imports decreased, influencing Lorazepam trade flows.
- Strong retail sales (5.42% in September 2025) supported consumer ability to afford Lorazepam healthcare expenses.
- The low unemployment rate (4.3% in September 2025) enhanced consumer disposable income for Lorazepam access.
- Declining consumer confidence in September 2025 suggested potential constraints on Lorazepam consumer spending.
- Chemical manufacturing economic conditions sentiment deteriorated further during Q3 2025.
Why did the price of Lorazepam change in September 2025 in North America?
- Increased raw material costs, evidenced by the 2.6% PPI rise in August 2025, pressured Lorazepam prices upward.
- Higher operational expenses, indicated by the 3.0% CPI increase in September 2025, contributed to rising Lorazepam costs.
- Shrinking chemical inventories in Q3 2025, coupled with natural gas price upticks, tightened Lorazepam supply.
Lorazepam Prices in APAC
- In China, the Lorazepam Price Index fell quarter-over-quarter, influenced by significant production cost reductions.
- Lorazepam production costs decreased in Q3 2025, driven by a -2.3% PPI year-on-year in September 2025.
- Demand for Lorazepam was supported by a 3.0% rise in retail sales year-on-year in September 2025.
- The Lorazepam demand outlook remained robust due to China's aging population and rising chronic diseases.
- China's Manufacturing Index contracted in September 2025, indirectly impacting the broader Lorazepam market.
- Industrial production increased by 6.5% year-on-year in September 2025, supporting healthcare spending.
- Trade flows faced challenges from US tariffs effective August 2025, impacting Lorazepam exports.
- Feedstock costs, including 1,4-Butanediol, weakened in July 2025, contributing to lower production expenses.
- Lower electricity prices in China in 2025 provided a cost advantage for Lorazepam manufacturers.
Why did the price of Lorazepam change in September 2025 in APAC?
- Production costs for Lorazepam decreased due to a -2.3% PPI year-on-year in September 2025.
- Deflationary pressures from a -0.3% CPI year-on-year in September 2025 impacted pharmaceutical pricing.
- Weakening 1,4-Butanediol costs in July 2025 contributed to overall lower Lorazepam production expenses.
Lorazepam Prices in Europe
- In Germany, Lorazepam Price Index fell in Q3 2025, influenced by suppressed feedstock and mixed demand.
- Lorazepam production costs faced downward pressure in Q3 2025, as PPI declined 1.7% in September.
- Rising CPI (2.4% in September 2025) signaled higher operational costs for Lorazepam producers.
- Demand for Lorazepam was moderately supported in Q3 2025 by pharmaceutical market growth and aging.
- Manufacturing Index contracted in September 2025, Industrial Production declining 1.0%, impacting supply.
- Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to persistent oversupply.
- Elevated natural gas and electricity prices in Europe pressured Lorazepam production costs.
- Consumer confidence deteriorated to -23.6 in September 2025, potentially impacting healthcare spending.
- Low unemployment (3.9%) in September 2025 supported consumer affordability for prescription medications.
- Retail sales grew 0.8% in September 2025, indicating slight consumer spending resilience.
Why did the price of Lorazepam change in September 2025 in Europe?
- Producer Price Index declined 1.7% in September 2025, reducing Lorazepam input costs in Europe.
- Benzene and Toluene feedstock costs remained suppressed in Q3 2025 due to oversupply, lowering production.
- Elevated natural gas and electricity prices in Q3 2025 increased operational costs for Lorazepam producers.
